¼¼°èÀÇ ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·á ½ÃÀå : À¯Çüº°, ÀûÀÀÁõº°, À¯·¡º°, ÃÖÁ¾»ç¿ëÀÚº° - ¿¹Ãø(-2029³â)
Autologous Stem Cell & Non-stem Cell Therapies Market by Type (CAR-T, Tumor Infiltrating Lymphocyte), Indication (Cancer, Musculoskeletal, Dermatology), Source (T-Cells, Mesenchymal Stem Cell), End User (Hospital) - Global Forecast to 2029
»óǰÄÚµå : 1491992
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 295 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,162,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,621,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,792,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2024³â 55¾ï ´Þ·¯¿¡¼­ 2029³â±îÁö 222¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 32.3% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀåÀº ÀÚ°¡ CAR-T ¼¼Æ÷ ±â¹Ý Ä¡·á¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Áõ°¡, ÀÚ°¡ ¼¼Æ÷ Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ R&D ÅõÀÚ Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2022-2029³â
±âÁØ ¿¬µµ 2023³â
¿¹Ãø ±â°£ 2024-2029³â
´ÜÀ§ ±Ý¾×(100¸¸ ´Þ·¯)
ºÎ¹® À¯Çüº°, ÀûÀÀÁõº°, À¯·¡º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

"ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¾Ï ȯÀÚÀÇ Áõ°¡¿Í ´Ù¾çÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù."

ÀÚ°¡ ºñÁٱ⼼Æ÷ Ä¡·áÀÇ Áö¹èÀûÀÎ Á¡À¯À²Àº Àü ¼¼°è ¾Ï ȯÀÚ Áõ°¡·Î ÀÎÇØ ÀÚ°¡ ºñÁٱ⼼Æ÷ Ä¡·á¿Í °°Àº È¿°úÀûÀÎ ¾Ï Ä¡·á ¼Ö·ç¼Ç °³¹ß¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Áõ°¡¿Í ½ÇÇà °¡´ÉÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¾Ï ȯÀÚ Áõ°¡·Î ÀÎÇØ ½ÃÀå¿¡¼­ÀÇ Æò°¡°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

"ÀûÀÀÁõº°·Î´Â ¾Ï ÀûÀÀÁõ ÇÏÀ§ ºÎ¹®ÀÌ 2023³â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù."

2023³â, ¾Ï ÀûÀÀÁõ ÇÏÀ§ ºÎ¹®Àº ÀûÀÀÁõ ºÎ¹®¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â Àü ¼¼°è ¾Ï ȯÀÚ ¼öÀÇ Áõ°¡¿Í ÀÚ°¡ CAR-T ¼¼Æ÷ Ä¡·á¿Í °°Àº È¿°úÀûÀ̰í È¿À²ÀûÀÎ ¾Ï Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇϸç, ÀÚ°¡ CAR-T ¼¼Æ÷ Ä¡·á´Â ´Ù¹ß¼º °ñ¼öÁ¾ ¹× ´Ù¾çÇÑ ¸²ÇÁÁ¾°ú °°Àº ´Ù¾çÇÑ ÇüÅÂÀÇ ¾Ï Ä¡·á¿¡ È¿°úÀûÀÓÀÌ ÀÔÁõµÆ½À´Ï´Ù.

"ºÏ¹Ì°¡ ½ÃÀå¿¡¼­ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù."

ºÏ¹Ì ÀÇ·á ºÎ¹®ÀÇ È®´ë, ¾Ï°ú °°Àº ¸¸¼º Áúȯ¿¡ ´ëÇÑ ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·áÀÇ ½ÂÀÎ ¹× »ç¿ë Áõ°¡, ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ ¿¬±¸¿¡ ´ëÇÑ ÇмúÀû, Á¶Á÷Àû °ü½ÉÀÇ Áõ°¡°¡ ºÏ¹Ì ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹ÌÀÇ ÅºÅºÇÑ Á¦¾à ÀÎÇÁ¶ó¿Í Gilead Sciences, Inc.(¹Ì±¹), Bristol-Myers Squibb Company(¹Ì±¹), Johnson & Johnson(¹Ì±¹)°ú °°Àº ½ÃÀå ¼±µµ ±â¾÷ÀÇ Á¸Àçµµ ÀÌ Áö¿ªÀÇ ¼±µµÀû ÁöÀ§¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­´Â ¼¼°è ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·á ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ÁÖ¿ä ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ, °æÀï »óȲ, ÇâÈÄ µ¿Çâ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·á ½ÃÀå : À¯Çüº°

Á¦7Àå ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·á ½ÃÀå : ÀûÀÀÁõº°

Á¦8Àå ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·á ½ÃÀå : À¯·¡º°

Á¦9Àå ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ÀÚ°¡ Áٱ⼼Æ÷/ºñÁٱ⼼Æ÷ Ä¡·á ½ÃÀå : Áö¿ªº°

Á¦11Àå °æÀï »óȲ

Á¦12Àå ±â¾÷ °³¿ä

Á¦13Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The autologous stem cell & non-stem cell therapies market is projected to reach USD 22.2 billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 32.3% during the forecast period. The growth of this market is driven by several factors such as the growing regulatory approvals for autologous CAR T cell-based therapies, increasing R&D investments for the development of autologous cell therapies, and an increase in the demand for personalized medicines.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Million
SegmentsBy Type, Indication, Source, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The autologous stem cell & non-stem cell therapies market growth for Autologous non-stem cell therapies can be attributed to the increasing number of cancer cases leading to increased demand for substantial treatment option."

The autologous stem cell & non-stem cell therapies market, based on type segment is further segmented into autologous stem cell therapies and autologous non-stem cell therapies. The autologous non-stem cell therapies sub-segment is further divided into CAR T cell therapies, Tumor Infiltrating Lymphocyte (TIL), and other therapies (of skin grafts, others). The autologous non-stem cell therapies hold the dominant share due to the rise in global cancer cases accelerating the demand for the development of effective cancer treatment solutions such as autologous non-stem-cell-based therapies, which are increasingly valued in the market due to the rising number of regulatory approvals for these therapies and growing number of cancer patients seeking viable treatment alternatives.

"By Indications, the cancer indication subsegment accounted for the largest share of the autologous stem cell & non-stem cell therapies market in 2023."

The indication segment is further segmented into cancer indications and non-cancer indications. In 2023, the cancer indications subsegment accounted for the largest share of the indication segment due to the rising number of global cancer cases, and a growing demand for the development of effective and efficient cancer therapeutics such as autologous CAR T cell therapies, that are shown to be effective for treating various forms of cancer such as multiple myeloma and various types of lymphoma.

"North American region is expected to register the highest CAGR in the autologous stem cell & non-stem cell therapies market."

The market for autologous stem cell & non-stem cell therapies in North America is estimated to grow at the highest rate during the forecast period. The rising academic and organizational interest in autologous stem cell and non-stem cell-based research, complemented by the North American healthcare sector's expansion and the rising approvals and utilization of autologous stem cell and non-stem cell-based therapies for cancer and other chronic diseases are factors that will aid the market growth in North America. North America also has an established pharmaceutical manufacturing infrastructure and the presence of prominent players in the autologous stem cell & non-stem cell therapies market such as Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US) among others which further supports the leadership position of this region.

The primary interviews conducted for this report can be categorized as follows:

List of Companies Profiled in the Report

Note: The above list is inexhaustive

Research Coverage:

This report provides a detailed picture of the autologous stem cell & non-stem cell therapies market. It aims to estimate the market's size and future growth potential across different segments such as the type, indication, source, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the autologous stem cell & non-stem cell therapies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autologous stem cell & non-stem cell therapies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE

7 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION

8 AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPIES MARKET, BY SOURCE

9 AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPIES MARKET, BY END USER

10 AUTOLOGOUS STEM CELL AND NON-STEM STEM CELL THERAPIES MARKET, BY REGION

11 COMPETITIVE LANDSCAPE

12 COMPANY PROFILES

13 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â